Enspryng FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (First approved August 14, 2020)
Brand name: Enspryng
Generic name: satralizumab-mwge
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Neuromyelitis Optica Spectrum Disorder
Enspryng (satralizumab-mwge) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Development Timeline for Enspryng
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.